Diversity of the apoptotic response to chemotherapy in childhood leukemia

被引:24
作者
Liu, T
Raetz, E
Moos, PJ
Perkins, S
Bruggers, CS
Smith, F
Carroll, WL
机构
[1] Univ Utah, Sch Med, Ctr Children Huntsman Canc Inst, Salt Lake City, UT USA
[2] Univ Utah, Sch Med, Dept Pediat, Div Pediat Hematol Oncol Primary Childrens Med Ct, Salt Lake City, UT USA
[3] Univ Utah, Sch Med, Dept Oncol Sci, Salt Lake City, UT USA
[4] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA
关键词
apoptosis; chemotherapy; childhood leukemia;
D O I
10.1038/sj.leu.2402360
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Apoptosis is the primary mechanism through which most chemotherapeutic agents induce tumor cell death. The purpose of this study was to determine the extent to which blasts from children with leukemia undergo a uniform apoptotic death pathway in vivo. The expression of pro- and anti-apoptotic proteins p53, p21, MDM-2, BCL-2, BCL-X-L, BCL-X-S, and BAX, and caspase-3 activity was determined in circulating blasts collected from the peripheral blood of children with leukemia prior to, and at serial time points following chemotherapy. Culturing blasts ex vivo for 12 h assessed spontaneous apoptosis and the increment induced by chemotherapy. Baseline apoptosis varied between 3% and 29%. Twenty-four hours following chemotherapy the increase in the percentage of cells undergoing apoptosis ranged from <1% to 38%. Eleven of 20 patients who received initial treatment with a p53-dependent drug showed an increase in p53 expression. In these patients, the levels of p53 target genes were also increased, A uniform pattern of BCL-2 family protein expression was not observed and only a minority of samples showed a change that would favor apoptosis. We conclude that that the initial apoptotic response to chemotherapy in children with leukemia is variable involving both p53-dependent and p53-independent pathways.
引用
收藏
页码:223 / 232
页数:10
相关论文
共 80 条
  • [51] MATSUBARA K, 1994, EUR J HAEMATOL, V52, P47
  • [52] Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
    McLeod, HL
    Krynetski, EY
    Relling, MV
    Evans, WE
    [J]. LEUKEMIA, 2000, 14 (04) : 567 - 572
  • [53] MIYASHITA T, 1993, BLOOD, V81, P151
  • [54] THE MDM-2 ONCOGENE PRODUCT FORMS A COMPLEX WITH THE P53 PROTEIN AND INHIBITS P53-MEDIATED TRANSACTIVATION
    MOMAND, J
    ZAMBETTI, GP
    OLSON, DC
    GEORGE, D
    LEVINE, AJ
    [J]. CELL, 1992, 69 (07) : 1237 - 1245
  • [55] Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/MORT1 signaling: Implications for cancer therapy
    Newton, K
    Strasser, A
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (01) : 195 - 200
  • [56] Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance
    Pepper, C
    Hoy, T
    Bentley, P
    [J]. LEUKEMIA & LYMPHOMA, 1998, 28 (3-4) : 355 - +
  • [57] Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo
    Prokop, A
    Wieder, T
    Sturm, I
    Essmann, E
    Seeger, K
    Wuchter, C
    Ludwig, WD
    Henze, G
    Dörken, B
    Daniel, PT
    [J]. LEUKEMIA, 2000, 14 (09) : 1606 - 1613
  • [58] CHILDHOOD LEUKEMIAS
    PUI, CH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (24) : 1618 - 1630
  • [59] REED JC, 1999, BCL 2 FAMILY PROTEIN
  • [60] Bcl-2 family members in childhood acute lymphoblastic leukemia:: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome
    Salomons, GS
    Smets, LA
    Verwijs-Janssen, M
    Hart, AAM
    Haarman, EG
    Kaspers, GJL
    Van Wering, ER
    Van Der Does-Van Den Berg, A
    Kamps, WA
    [J]. LEUKEMIA, 1999, 13 (10) : 1574 - 1580